GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion. The wide-ranging ...
The threat of tariffs has loomed over countries and industries alike during Trump’s second administration. But with a potential 200% tariff on pharmaceutical imports into the US – which could affect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback